亚临床感染
甲状腺
格雷夫斯病
沃尔夫-柴柯夫效应
甲状腺炎
内科学
医学
激素
内分泌学
甲状腺切除术
亚急性甲状腺炎
抗甲状腺药物
胃肠病学
甲状腺机能正常
作者
Layal Chaker,David S. Cooper,John P. Walsh,Robin P. Peeters
出处
期刊:The Lancet
[Elsevier BV]
日期:2024-01-23
卷期号:403 (10428): 768-780
被引量:28
标识
DOI:10.1016/s0140-6736(23)02016-0
摘要
Thyrotoxicosis causes a variety of symptoms and adverse health outcomes. Hyperthyroidism refers to increased thyroid hormone synthesis and secretion, most commonly from Graves' disease or toxic nodular goitre, whereas thyroiditis (typically autoimmune, viral, or drug induced) causes thyrotoxicosis without hyperthyroidism. The diagnosis is based on suppressed serum concentrations of thyroid-stimulating hormone (TSH), accompanied by free thyroxine and total or free tri-iodothyronine concentrations, which are raised (overt hyperthyroidism) or within range (subclinical hyperthyroidism). The underlying cause is determined by clinical assessment, detection of TSH-receptor antibodies and, if necessary, radionuclide thyroid scintigraphy. Treatment options for hyperthyroidism include antithyroid drugs, radioactive iodine, and thyroidectomy, whereas thyroiditis is managed symptomatically or with glucocorticoid therapy. In Graves' disease, first-line treatment is a 12–18-month course of antithyroid drugs, whereas for goitre, radioactive iodine or surgery are preferred for toxic nodules or goitres. Evidence also supports long-term treatment with antithyroid drugs as an option for patients with Graves' disease and toxic nodular goitre.
科研通智能强力驱动
Strongly Powered by AbleSci AI